Cited by 669Virus-based gene therapy researchImmunotherapy and Immune ResponsesSARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 132 of the 134 references it cites were found in a registry or an index.

Adenoviruses as vaccine vectors

Open access

Tatsis, Nia, Ertl, Hildegund C.J.·2004·Molecular Therapy

DOI 10.1016/j.ymthe.2004.07.013PMC PMC7106330

Open this paper in CoChat — free account

Abstract

Adenoviruses have transitioned from tools for gene replacement therapy to bona fide vaccine delivery vehicles. They are attractive vaccine vectors as they induce both innate and adaptive immune responses in mammalian hosts. Currently, adenovirus vectors are being tested as subunit vaccine systems for numerous infectious agents ranging from malaria to HIV-1. Additionally, they are being explored as vaccines against a multitude of tumor-associated antigens. In this review we describe the molecular biology of adenoviruses as well as ways the adenovirus vectors can be manipulated to enhance their efficacy as vaccine carriers. We describe methods of evaluating immune responses to transgene products expressed by adenoviral vectors and discuss data on adenoviral vaccines to a selected number of pathogens. Last, we comment on the limitations of using human adenoviral vectors and provide alternatives to circumvent these problems. This field is growing at an exciting and rapid pace, thus we have limited our scope to the use of adenoviral vectors as vaccines against viral pathogens.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2004.07.013

Cites

132 of 132 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Characteristics of a human cell line transformed by DNA from human adenovirus type 5
Graham, F. L., Russell, W. C., Smiley, J., & Nairn, R. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-1-59 · Cited by 4,793
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“3 , are now available [61] [62] [63] [64] .”
Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt‐Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102
Innate immune recognition: mechanisms and pathways
Medzhitov, R., & Janeway, C. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.917309.x · Cited by 1,589
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
Shiver, J. W., Fu, T., Chen, L., Casimiro, D. R., Davies, M.-E., Evans, R. K., Zhang, Z., Simon, A. J., Trigona, W. L., Dubey, S. A., et al. (2002) · Nature · doi:10.1038/415331a · Cited by 1,173
Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
Yang, Y., Li, Q., Ertl, H. C. J., & Wilson, J. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.4.2004-2015.1995 · Cited by 1,033
Self-citation
A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong
TSANG, K. W. T., Ho, P., OOI, G. C., Yee, W. K. S., Wang, T., Chan-Yeung, M. M. W., Lam, W. K., Seto, W., Yam, L. Y.-C., CHEUNG, T. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030666 · Cited by 1,018
CD46 is a cellular receptor for group B adenoviruses
Gaggar, A., Shayakhmetov, D. M., & Lieber, A. (2003) · Nature Medicine · doi:10.1038/nm952 · Cited by 793
Development of a preventive vaccine for Ebola virus infection in primates
Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z., & Nabel, G. J. (2000) · Nature · doi:10.1038/35046108 · Cited by 655

Flagged first, then by citations

Show all 134 references

2 of the 134 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Fisher, 2000, Protection and retargeting of adenovirus using a multifunctional hydrophilic polymer, Mol. Ther., 1S, 57

Sorted by citations

Items 301–400 of 665

AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection
Logan, G. J., Wang, L., Zheng, M., Cunningham, S. C., Coppel, R. L., & Alexander, I. E. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.09.072 · Cited by 22
CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells
Li, Y., Li, Y., Si, C.-Z., Zhu, Y.-H., Jin, Y., Zhu, T., Liu, M., & Liu, G. (2016) · Virus Research · doi:10.1016/j.virusres.2016.05.002 · Cited by 21
Older adults: panoramic view on the COVID-19 vaccination
Andryukov, B. G., & Besednova, N. N. (2021) · AIMS Public Health · doi:10.3934/publichealth.2021030 · Cited by 23
Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine
Gabitzsch, E. S., Xu, Y., Balint, J. P., Balcaitis, S. D., Sanders-Beer, B. E., & Jones, F. R. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.08.038 · Cited by 21
Viable adenovirus vaccine prototypes: High-level production of a papillomavirus capsid antigen from the major late transcriptional unit
Berg, M. G., DiFatta, J., Hoiczyk, E., Schlegel, R., & Ketner, G. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500933102 · Cited by 21
Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of aPlasmodium falciparumProtein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1
Rodrı́guez, A., Goudsmit, J., Companjen, A. R., Mintardjo, R., Gillissen, G. F., Tax, D., Sijtsma, J. C., Weverling, G. J., Holterman, L., Lanar, D. E., et al. (2008) · Infection and Immunity · doi:10.1128/iai.01614-07 · Cited by 21
Developing the next-generation of adenoviral vector vaccines
Sampson, A., Hlaváč, M., Gillman, A. C. T., Douradinha, B. G., & Gilbert, S. C. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2514356 · Cited by 25
Codon Usage and Adenovirus Fitness: Implications for Vaccine Development
Gimenez–Roig, J., Núñez-Manchón, E., Alemany, R., Villanueva, E., & Fillat, C. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.633946 · Cited by 21
Two replication-defective adenoviral vaccine vectors for the induction of immune responses to PPRV
Rojas, J. M., Moreno, H., García, A., Ramírez, J. C., Sevilla, N., & Martı́n, V. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.11.033 · Cited by 20
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo
Morse, M. A., Wei, J.-P., Hartman, Z. C., Xia, W., Ren, X., Lei, G., Barry, W. T., Osada, T., Hobeika, A. C., Peplinski, S., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24995 · Cited by 19
DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect
Perez‐Trujillo, J. J., Garza-Morales, R., Barron-Cantu, J. A., Figueroa‐Parra, G., García‐García, A., Rodríguez‐Rocha, H., García‐Juárez, J., Muñoz-Maldonado, G. E., Cárdenas, O. S., Montes‐de‐Oca‐Luna, R., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.5635 · Cited by 20
Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine
Haut, L. H., & Ertl, H. C. J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0209094 · Cited by 20
Self-citation
Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy
Tessarollo, N. G., Domingues, A. C. M., Antunes, F., da Luz, J. C. D. S., Rodrigues, O. A., Cerqueira, O. L. D., & Strauss, B. E. (2021) · Cancers · doi:10.3390/cancers13081863 · Cited by 19
Gene Therapy Cargoes Based on Viral Vector Delivery
Lundstrom, K. H. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220921112753 · Cited by 19
In vivo tracking of adenoviral-transduced iron oxide-labeled bone marrow-derived dendritic cells using magnetic particle imaging
Fink, C., Gevaert, J. J., Barrett, J. W., Dikeakos, J. D., Foster, P. J., & Dekaban, G. A. (2023) · European Radiology Experimental · doi:10.1186/s41747-023-00359-4 · Cited by 21
Challenges of bacteriophages application in controlling bacterial plant diseases and how to overcome them
Halawa, E. M. (2023) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-023-00549-y · Cited by 19
Immunotherapy in colorectal cancer: Statuses and strategies
Li, Y., Cheng, Z., Li, S., & Zhang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41354 · Cited by 24
Cancer vaccines: an update on recent achievements and prospects for cancer therapy
Chekaoui, A., Garofalo, M., Gad, B., Staniszewska, M., Chiaro, J., Pancer, K. W., Gryciuk, A., Cerullo, V., Salmaso, S., Caliceti, P., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01541-7 · Cited by 21
CD8 + T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis
Wang, Q., Klinke, D. J., & Wang, Z. (2015) · BMC Systems Biology · doi:10.1186/s12918-015-0168-9 · Cited by 19
Delivery of Antigens by Viral Vectors for Vaccination
Krause, A., & Worgall, S. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.84 · Cited by 20
Construction and Preparation of Three Recombinant Adenoviruses Expressing Truncated NS3 and Core Genes of Hepatitis C Virus for Vaccine Purposes
Hosseini, S. Y., Sabahi, F., Moazzeni, S. M., Modarressi, M. H., Firoozi, M. S., & Ravanshad, M. (2012) · Hepatitis Monthly · doi:10.5812/hepatmon.6130 · Cited by 19
A Bivalent Human Adenovirus Type 5 Vaccine Expressing the Rabies Virus Glycoprotein and Canine Distemper Virus Hemagglutinin Protein Confers Protective Immunity in Mice and Foxes
Yan, L., Zhao, Z., Xue, X., Zheng, W., Xu, T., Liu, L., Tian, L., Wang, X., He, H., & Zheng, X. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01070 · Cited by 19
A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates
Guo, C. M., Peng, Y., Lin, L., Pan, X., Fang, M., Zhao, Y., Bao, K., Li, R., Han, J.-B., Chen, J., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100448 · Cited by 20
Large-Scale Purification and Crystallization of Adenovirus Hexon
Rux, J. J., & Burnett, R. M. (2007) · Methods in molecular medicine · doi:10.1007/978-1-59745-277-9_17 · Cited by 19
Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
Wang, D., Molavi, O., Lutsiak, M. E. C., Elamanchili, P., Kwon, G. S., & Samuel, J. (2007) · PubMed · Cited by 19
Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2
Lin, Y., Liao, X., Cao, X., Zhang, Z., Wang, X., He, X., Liao, H., Ju, B., Qi, F., Xu, H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci175233 · Cited by 19
In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?
Echeverría, N., Comas, V., Aldunate, F., Perbolianachis, P., Moreno, P., & Cristina, J. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i10.1234 · Cited by 22
A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants
Rabaan, A. A., Mutair, A. S. A., Hajissa, K., Alfaraj, A. H., Al-Jishi, J. M., Alhajri, M. M., Alwarthan, S. M., Alsuliman, S. A., Al-Najjar, A. H., Al-Zaydani, I. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10101655 · Cited by 18
Viral Vectors in Gene Replacement Therapy
Minskaia, E., Galieva, A., Egorov, A. D., Ivanov, R. A., & Karabelsky, A. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923120179 · Cited by 19
Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection
Sharma, A., Wendland, R. L., Sung, B., Wu, W., Grünwald, T., & Worgall, S. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.08.049 · Cited by 19
The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector
Millar, J., Dissanayake, D., Yang, T. C., Grinshtein, N., Evelegh, C. M., Wan, Y., & Bramson, J. L. (2007) · Cellular Immunology · doi:10.1016/j.cellimm.2008.01.005 · Cited by 18
Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections
Koger-Pease, C., Perera, D. J., & Ndao, M. (2023) · Pharmaceuticals · doi:10.3390/ph16030334 · Cited by 18
Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 Hexon
Su, X., Tian, X., Jiang, Z., Ma, Q., Liu, Q., Lu, X., & Zhou, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156984 · Cited by 17
Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization
Penaloza‐MacMaster, P., Alayo, Q. A., Ra, J., Provine, N. M., Larocca, R. A., Lee, B., & Barouch, D. H. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.08.048 · Cited by 17
Chimpanzee adenoviral vector prime-boost regimen elicits potent immune responses against Ebola virus in mice and rhesus macaques
Yang, X., Wang, X., Song, Y., Zhou, P., Li, D., Zhang, C., Jin, X., Huang, Z. W., & Zhou, D. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1644968 · Cited by 17
Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
Garofalo, M., Staniszewska, M., Salmaso, S., Caliceti, P., Pancer, K. W., Wieczorek, M., & Kuryk, Ł. (2020) · Vaccines · doi:10.3390/vaccines8020293 · Cited by 17
Innate immune response after adenoviral gene delivery into skin is mediated by AIM2, NALP3, DAI and mda5
Schulte, M., Sorkin, M., Al‐Benna, S., Stupka, J., Hirsch, T., Daigeler, A., Kesting, M. R., Steinau, H., Jacobsen, F., & Steinstraesser, L. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-234 · Cited by 17
Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity
Moore, A., & Hutchings, C. L. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.1.111 · Cited by 17
Methods for the Production of First Generation Adenoviral Vectors
Palmer, D. J., & Ng, P. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-237-3_4 · Cited by 17
Vaccine formulation design: challenges and opportunities
Zafar, S., Akhtar, A., Sayed, E., Onaiwu, E., Arshad, M. S., & Ahmad, Z. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00017c · Cited by 17
Utilization of Viral Vector Vaccines in Preparing for Future Pandemics
Hofmeyer, K. A., Bianchi, K. M., & Wolfe, D. (2022) · Vaccines · doi:10.3390/vaccines10030436 · Cited by 16
An overview: CRISPR/Cas-based gene editing for viral vaccine development
Bhujbal, S. S., Bhujbal, R., & Giram, P. S. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2112952 · Cited by 16
Antigen-capturing oncolytic adenoviruses along with IDO blockade for improved tumor immunotherapy
Chen, X., Cheng, K., Wang, X., Liu, J., Liang, J., Liu, G., Lu, Y., Tang, M., Qian, D., Chen, L., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101922 · Cited by 16
Immunogenicity and protective efficacy of recombinant adenovirus expressing a novel genotype G2b PEDV spike protein in protecting newborn piglets against PEDV
Song, X., Zhou, Q. Y., Zhang, J., Chen, T., Deng, G., Yue, H., Tang, C., Wu, X., Yu, J., & Zhang, B. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02403-23 · Cited by 16
Construction and Immunogenicity of Recombinant Adenovirus Vaccines Expressing the HMW1, HMW2, or Hia Adhesion Protein of NontypeableHaemophilus influenzae
Winter, L. E., & Barenkamp, S. J. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00115-10 · Cited by 16
Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform
Salisch, N. C., Vujadinovic, M., van der Helm, E., Spek, D., Vorthoren, L., Serroyen, J., Kuipers, H., Schuitemaker, H., Zahn, R. C., Custers, J. H. H. V., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174728 · Cited by 16
HIV T-Cell Vaccines
Mothe, B., & Brander, C. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0484-2_2 · Cited by 16
Viral Mimicry as a Design Template for Nucleic Acid Nanocarriers
de la Fuente, I. F., Sawant, S. S., Tolentino, M. Q., Corrigan, P. M., & Rouge, J. L. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.613209 · Cited by 17
Corona and Reproduction, or Why the Corona Vaccination Does Not Result in Infertility
Braun, A.-S., Feil, K., Reiser, E., Weiß, G., von Steuben, T., Pinggera, G., Köhn, F., & Tóth, B. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1750-9284 · Cited by 15
Development of vaccines for Marburg hemorrhagic fever
Bausch, D. G., & Geisbert, T. W. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.1.57 · Cited by 15
The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants
Damasceno, D. H. P., Amaral, A. A., Silva, C. A., & Silva, A. C. S. E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210902094254 · Cited by 15
Intranasal delivery of a recombinant adenovirus vaccine encoding the PEDV COE elicits potent mucosal and systemic antibody responses in mice
Yan, S., Luo, Y. M., Zhan, N., Xu, H., Yao, Y., Liu, X., Dong, X., Li, K., Zhang, G., & Liu, P. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00692-24 · Cited by 15
Respiratory delivered vaccines: Current status and perspectives in rational formulation design
Wu, L., Xu, W., Jiang, H., Yang, M., & Cun, D. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.08.026 · Cited by 19
Potential of helper-dependent adenoviral vectors in modulating airway innate immunity.
Kushwah, R., Cao, H., & Hu, J. (2007) · PubMed · Cited by 15
Metabolic flux profiling of MDCK cells during growth and canine adenovirus vector production
Carinhas, N., Pais, D. A. M., Koshkin, A., Fernandes, P., Coroadinha, A. S., Carrondo, M. J. T., Alves, P. M., & Teixeira, A. P. (2016) · Scientific Reports · doi:10.1038/srep23529 · Cited by 15
Frontrunners in the race to develop a SARS-CoV-2 vaccine
Russell, R., Pelka, P., & Mark, B. L. (2020) · Canadian Journal of Microbiology · doi:10.1139/cjm-2020-0465 · Cited by 15
SARS-CoV-2: Overview and Its Impact on Oral Health
Ting, M., & Suzuki, J. B. (2021) · Biomedicines · doi:10.3390/biomedicines9111690 · Cited by 16
Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
D’Alise, A. M., Leoni, G., Lucia, M. D., Langone, F., Nocchi, L., Tucci, F. G., Micarelli, E., Cotugno, G., Troise, F., Garzia, I., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003480 · Cited by 15
Biobased Monoliths for Adenovirus Purification
Fernandes, C. S. M., Gonçalves, B. L., Sousa, M., Martins, D. L., Barroso, T., Pina, A. S., Peixoto, C., Aguiar‐Ricardo, A., & Roque, A. C. A. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/am508907b · Cited by 15
COVID-19: Myths and Reality
Kordyukova, L. V., & Shanko, A. V. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921070026 · Cited by 13
Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery
Kaulfuß, M., Wensing, I., Windmann, S., Hrycak, C. P., & Bayer, W. (2017) · Retrovirology · doi:10.1186/s12977-017-0336-7 · Cited by 14
Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen
Haq, K., Jia, Y., Elahi, S. M., MacLean, S., Akache, B., Gurnani, K., Chattopadhyay, A., Nazemi-Moghaddam, N., Gilbert, R., McCluskie, M. J., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.08.079 · Cited by 14
Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection
Wang, X., Zhou, P., Wu, M., Yang, K., Guo, J., Wang, X., Li, J., Fang, Z., Wang, G., Xing, M., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0206-5 · Cited by 14
Robust genital gag‐specific CD8+ T‐cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV‐1‐gag
Haut, L. H., Lin, S. W., Tatsis, N., DiMenna, L. J., Giles‐Davis, W., Pinto, A. R., & Ertl, H. C. J. (2010) · European Journal of Immunology · doi:10.1002/eji.201040440 · Cited by 14
Self-citation
Antibody responses to prime–boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140
Emmer, K. L., Wieczorek, L., Tuyishime, S., Molnar, S., Polonis, V. R., & Ertl, H. C. J. (2016) · AIDS · doi:10.1097/qad.0000000000001224 · Cited by 14
Self-citation
Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivector
He, Y., & Falo, L. D. (2006) · Immunologic Research · doi:10.1385/ir:36:1:101 · Cited by 14
A “Prime and Deploy” Strategy for Universal Influenza Vaccine Targeting Nucleoprotein Induces Lung-Resident Memory CD8 T cells
Chung, H., Kim, E.-A., & Chang, J. (2021) · Immune Network · doi:10.4110/in.2021.21.e28 · Cited by 13
Single-dose of a replication-competent adenovirus-vectored vaccine provides sterilizing protection against Rift Valley fever virus challenge
Bian, T., Wang, B., Fu, G., Hao, M., Chen, Y., Fang, T., Liu, S., Yu, C., Li, J., & Chen, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907675 · Cited by 13
Gene‐encoded nanoparticle vaccine platforms for in vivo assembly of multimeric antigen to promote adaptive immunity
Tursi, N. J., Xu, Z., Kulp, D. W., & Weiner, D. B. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1880 · Cited by 13
Nanotechnology and CRISPR/Cas-Mediated Gene Therapy Strategies: Potential Role for Treating Genetic Disorders
Kaur, G., Arora, J., Sodhi, A. S., Bhatia, S., & Batra, N. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01301-8 · Cited by 14
Construction and Characterization of E1- and E3-Deleted Adenovirus Vectors Expressing Two Antigens from Two Separate Expression Cassettes
Small, J. C., Kurupati, R. K., Zhou, X., Bian, A., Chi, E., Li, Y., Xiang, Z., & Ertl, H. C. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.216 · Cited by 13
Self-citation
Scalable Production of Adenovirus Vectors
Silva, A. C., Fernandes, P., Sousa, M. F. Q., & Alves, P. M. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-679-5_13 · Cited by 13
SARS-CoV-2 vaccine development and how Brazil is contributing
Kanno, A. I., Barbosa, M. M. F., Moraes, L., & Leite, L. C. C. (2021) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2020-0320 · Cited by 15
AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice
Stebbings, R., Armour, G., Pettis, V., & Goodman, J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.028 · Cited by 13
Promiscuous Inflammasomes: The False Dichotomy of RNA/DNA Virus-Induced Inflammasome Activation and Pyroptosis
Wallace, H. L., & Russell, R. S. (2022) · Viruses · doi:10.3390/v14102113 · Cited by 15
Seroprevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Patients with Neuromuscular Disorders
Klann, P. J., Wang, X., Elfert, A., Zhang, W., Köhler, C., Güttsches, A., Jacobsen, F., Weyen, U., Roos, A., Ehrke‐Schulz, E., et al. (2022) · Viruses · doi:10.3390/v15010079 · Cited by 13
DNA-Based Influenza Vaccines as Immunoprophylactic Agents Toward Universality
Zhang, H., & Zowalaty, M. E. E. (2015) · Future Microbiology · doi:10.2217/fmb.15.110 · Cited by 13
Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule
Rollier, C. S., Spencer, A. J., Søgaard, K. C., Honeycutt, J. D., Furze, J. M., Bregu, M., Gilbert, S. C., Wyllie, D. H., & Hill, A. V. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-61730-8 · Cited by 14
CRISPR/Cas systems usher in a new era of disease treatment and diagnosis
Li, R., Wang, Q., She, K., Lu, F., & Yang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00095-y · Cited by 13
Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform
Gabitzsch, E. S., Balint-Junior, J. P., Xu, Y., Balcaitis, S. D., Sanders-Beer, B. E., Karl, J. A., Weinhold, K. J., Paessler, S., & Jones, F. R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.09.058 · Cited by 12
Generation and Evaluation of Recombinant Thermostable Newcastle Disease Virus Expressing the HA of H9N2 Avian Influenza Virus
Zhang, X., Bo, Z., Meng, C., Chen, Y., Zhang, C., Cao, Y., & Wu, Y. (2021) · Viruses · doi:10.3390/v13081606 · Cited by 12
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex
Dagotto, G., Ventura, J. D., Martinez, D. R., Anioke, T., Chung, B., Siamatu, M., Barrett, J., Miller, J. J., Schäfer, A., Yu, J., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00553-2 · Cited by 12
Three‐in‐One Oncolytic Adenovirus System Initiates a Synergetic Photodynamic Immunotherapy in Immune‐Suppressive Cholangiocarcinoma
Wang, J., Zhu, Y., Chen, Y., Huang, Y., Guo, Q., Wang, Y., Chen, A., Zhou, Y., Xu, L., Wang, L., et al. (2023) · Small · doi:10.1002/smll.202207668 · Cited by 12
Autophagy enhances antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein
Yan, Y., Liu, N., Lu, L., ZANG, C.-M., Shao, B., Li, Y., Wen, Y., Wei, Y., & Cheng, P. (2013) · Oncology Reports · doi:10.3892/or.2013.2531 · Cited by 12
Development of Streptococcus pneumoniae Vaccines Using Live Vectors
Wang, S., & Curtiss, R. (2014) · Vaccines · doi:10.3390/vaccines2010049 · Cited by 12
Skeletal Muscle Metabolism in the Pathology and Treatment of Type 1 Diabetes
Mann, C., Ayuso, E., Anguela, X. M., & Bosch, F. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790883435 · Cited by 12
Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections
Zhou, D., & Ertl, H. C. J. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.1.63 · Cited by 12
Self-citation
An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease
Dold, C., Marsay, L., Wang, N., Silva-Reyes, L., Clutterbuck, E., Paterson, G. K., Sharkey, K., Wyllie, D. H., Beernink, P. T., Hill, A. V. S., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade3901 · Cited by 11
Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants
Xing, M., Wang, Y., Wang, X., Liu, J., Dai, W., Hu, G., He, F., Zhao, Q., Li, Y., Sun, L., et al. (2023) · Journal of Virology · doi:10.1128/jvi.00724-23 · Cited by 12
Vaccines for Respiratory Viruses—COVID and Beyond
Rajanala, K., & Upadhyay, A. (2024) · Vaccines · doi:10.3390/vaccines12080936 · Cited by 10
Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection.
Ghasemi, F., Rostami, S., Ghayour‐Mobarhan, M., & Meshkat, Z. (2016) · PubMed Central · Cited by 11
Understanding the viral load during the synthesis and after rebinding of virus imprinted particles via real-time quantitative PCR
Gast, M., Kühner, S., Sobek, H., & Mizaikoff, B. (2018) · The Analyst · doi:10.1039/c8an00300a · Cited by 11
Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties
Daussy, C. F., Pied, N., & Wodrich, H. (2021) · Viruses · doi:10.3390/v13071221 · Cited by 12
Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines
Diamanti, A. P., Rosado, M. M., Nicastri, E., Sesti, G., Pioli, C., & Laganà, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708848 · Cited by 11
A Case of Leukocytoclastic Vasculitis Following SARS-COV-2 Vaccination
Ball‐Burack, M., & Kosowsky, J. M. (2021) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2021.10.005 · Cited by 12
Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics
Farhad, T., Neves, K., Arbuthnot, P. B., & Maepa, M. B. (2022) · Genes · doi:10.3390/genes13111941 · Cited by 11
Adenovirus Vectors for Renal-Targeted Gene Delivery
Appledorn, D. M., Seregin, S. S., & Amalfitano, A. (2008) · KARGER eBooks · doi:10.1159/000125581 · Cited by 11
Technologies for making new vaccines
Ellis, R. W., Rappuoli, R., & Ahmed, S. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00013-6 · Cited by 11
Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice
Karan, D. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.09.037 · Cited by 11
Tomorrow’s vector vaccines for small ruminants
Kyriakis, C. S. (2015) · Veterinary Microbiology · doi:10.1016/j.vetmic.2015.08.003 · Cited by 11

Authors: Tatsis, N., & Ertl, H. C. J.
Affiliations: The Wistar Institute (US)
Corresponding author: Ertl, Hildegund C.J.
ORCID: Ertl, Hildegund C.J.
Venue: Molecular Therapy
Publisher: Elsevier BV
Published: 2004-10
Volume: 10
Issue: 4
Pages: 616-629
ISSN: 1525-0016 (ISSN-L)
DOI: 10.1016/j.ymthe.2004.07.013
PMC: PMC7106330
OpenAlex: W1972258033
Cited by: 669
References: 134
Citations by year: 2026: 16 · 2025: 28 · 2024: 31 · 2023: 60 · 2022: 58 · 2021: 69 · 2020: 26 · 2019: 25 · 2018: 19 · 2017: 20 · 2016: 26 · 2015: 24 · 2014: 21 · 2013: 28 · 2012: 23
FWCI: 3.15
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 4389 d)
Locations: Molecular Therapy (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords: adenoviral vector, vaccine vectors, subunit vaccine, viral vaccines, innate immune response, adaptive immune response, transgene expression, HIV-1 vaccine, malaria vaccine, tumor-associated antigens
MeSH terms: Adenoviridae, Adenoviridae Infections, Genes, Viral, Genetic Vectors, Humans, Peptides, Viral Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adenoviruses as vaccine vectors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks